$21.70 -0.26 (-1.18%)
12/3/2009 4:00 PM

Affymax, Inc. (AFFY)

CAPS Rating: 1 out of 5

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

Current Price $21.70 Mkt Cap $414.95M
Open $22.10 P/E Ratio 1.83
Prev. Close $21.96 Div. (Yield) N/A (N/A)
Daily Range $21.60 - $22.81 Volume 97,514
52-Wk Range $8.52 - $25.15 Avg. Daily Vol. 137,000

AFFY News and Commentary

Related News and Articles

Caps

How do you think AFFY will perform vs the S&P 500?

Add Stock to Watchlist

All Members

38 Outperform
35 Underperform
 

All-Star Members

12 Outperform
16 Underperform
 

Wall Street

5 Outperform
0 Underperform
 

Top AFFY Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.57)
Submitted November 24, 2008

I continue my attempts to gauge Affymax swings. Now that they are back in the low end of range, I'm going to guess that they survive the current market unpleasantness without plumbing new lows thanks to a relatively strong cash position and the… More

1 Comment | Reply | Report this Post

NetscribeBiotech (36.11)
Submitted March 27, 2007

Affymax is a biopharmaceutical company creating peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The company was spun out from GlaxoSmithKline in 2001. The company does not have any approved product in… More

1 Comment | Reply | Report this Post
AFFY VS S&P 500 (SPY)

Fools bullish on AFFY are also bullish on:

Fools bearish on AFFY are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about AFFY.

Recs

0
Member Avatar crichton1 (38.59) Submitted: 10/9/2009 5:54:26 PM : Outperform Start Price: $22.79 AFFY Score: -7.21

competitive product to Amgen's EPO on the horizon.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar power2macs (< 20) Submitted: 7/8/2009 3:13:37 AM : Outperform Start Price: $17.84 AFFY Score: -3.56

the co hasnt had any major catalysts for a while since its in the middle of a moderately large phase iii program. as the market begins to remember that affys pivotal data is coming up it will also recall that the market for their drug hematide is absolutely massive.

there are some caveats to the large mkt opp (jnj litigation, potential generic biologics legislation, and a stagnant market for ESAs), but despite this the co remains dramatically undervalued, particularly considering their $150m cash balance (which mgmt has said will not be sufficient to carry them thru to profitability tho).

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar cashsage (86.16) Submitted: 6/2/2009 6:41:45 AM : Underperform Start Price: $17.27 AFFY Score: -7.50

AFFY has a too high valuation compared to its sales potential. It is also one of the most loss making companies at least until 2010.
Moreover the company has less than 150 shareholders, 128, on 2009-03-12, and the company is diluting the existing shareholders, adding 24% more outstanding shares from 2008-03 to 2009-03.

Report this Post 0 Comments | Reply | Permalink
View All 8 Pitches »

Leaderboard

Find the members with the highest scoring picks in AFFY.

Score Leader

zzlangerhans

zzlangerhans (99.57) Score: +146.22

Good example here of playing a biotech in both directions - only way to beat the field

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
pottou < 20 4/15/2008 Outperform 3M $13.51 +60.62% -14.02% +74.65
equalfuture 43.46 4/10/2008 Outperform 5Y $13.82 +57.02% -15.45% +72.47 1 Comment
hmlamo 68.74 4/14/2008 Outperform 1Y $13.68 +58.63% -13.83% +72.46
2st5 89.80 1/8/2009 Outperform NS $11.66 +86.11% +24.91% +61.20
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. peteshndl 69.06 6/16/2008 10/13/2009 Outperform 1Y $17.18 +26.31% -16.29% +42.59
isakk 65.34 6/17/2008 Outperform 3Y $17.35 +25.07% -16.40% +41.47
ugrmdclr < 20 7/21/2008 Outperform NS $19.65 +10.43% -9.97% +20.40
NetscribeBiotech 36.11 3/27/2007 Underperform 1Y $34.00 -36.18% -18.46% +17.71 2 Comments
kagame 76.80 12/13/2007 Outperform 5Y $22.85 -5.03% -22.03% +17.00
marcet 69.03 6/11/2009 Outperform 5Y $16.13 +34.53% +17.92% +16.61
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackStanfordRes 80.47 9/24/2008 Outperform NS $18.90 +14.81% -4.80% +19.62
TrackRWBaird 79.67 7/2/2008 Outperform NS $16.15 +34.37% -11.66% +46.03
TrackRBCCapMkts 81.80 7/17/2007 Outperform NS $27.56 -21.26% -25.17% +3.91
TrackCowenandCo 71.75 3/14/2007 Outperform NS $31.50 -31.11% -15.37% -15.75

Featured Broker Partners